Article Figures & Data
Figures
- Figure 1
- Multidrug-resistant and extended-spectrum beta lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates, stratified by gender. MDR: multidrug-resistant, E. coli: Escherichia coli, K. pnemoniae: Klebsiella pneumoniae, ESBL: extended-spectrum beta lactamase
Tables
Age groups (in years) Males (n=101) Females (n=509) P-values <1 47 (46.6) 125 (24.6) <0.001 1-5 27 (26.7) 190 (37.3) 0.042 6-15 27 (26.7) 194 (38.1) 0.029 Values are presented as numbers and percentages (%).
Species ↓ Males Females Total by species Escherichia coli 51 (50.5) 421 (82.7) 472 (77.4) Klebsiella species 29 (28.7) 53 (10.4) 82 (13.4) Proteus mirabilis 6 (5.9) 15 (2.9) 21 (3.4) Pseudomonas aeruginosa 5 (4.9) 4 (0.8) 9 (1.5) Citrobacter koseri 1 (1.0) 4 (0.8) 5 (0.8) Enterococcus species 2 (2.0) 4 (0.8) 6 (0.9) Enterobacter cloacae 4 (4.0) 2 (0.4) 6 (0.9) Salmonella species 2 (2.0) 2 (0.4) 4 (0.7) Achromobacter xylosoxidans 1 (1.0) 0 (0.0) 1 (0.2) MRSA 0 (0.0) 1 (0.2) 1 (0.2) Myroides species 0 (0.0) 1 (0.2) 1 (0.2) Acinetobacter baumannii 0 (0.0) 1 (0.2) 1 (0.2) Streptococcus agalactiae 0 (0.0) 1 (0.2) 1 (0.2) Total by gender 101 (100) 509 (100) 610 (100) Values are presented as numbers and percentages (%).
MRSA: Methicillin-resistant Staphylococcus aureus
- Table 3
- Escherichia coli verses non-Escherichia coli isolates, stratified by gender (p<0.001).
Species ↓ Males (n=101) Females (n=509) E. coli 51 (50.5) 421 (82.7) Non-E. coli 50 (49.5) 88 (17.3) Values are presented as numbers and percentages (%).
E. coli: Escherichia coli
- Table 4
- Resistance patterns of Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates, stratified by gender.
Species Antibiotic ↓ Males Females P-values No. of isolates tested Non-susceptible No. of isolates tested Non-susceptible E. coli Ampicillin 41 33 (80.5)* 324 200 (61.7) 0.018 Ceftriaxone 46 17 (37.0)* 412 88 (21.4) 0.016 Ciprofloxacin 42 22 (52.4)* 398 93 (23.4) <0.001 Imipenem 17 0 (0.0)* 88 0 (0.0) N/A Meropenem 17 0 (0.0)* 89 0 (0.0) N/A Nitrofurantoin 42 1 (2.4)* 407 15 (3.7) 0.664 TZP 8 0 (0.0)* 54 3 (5.6) 0.494 TMP/SMX 44 21 (47.7)* 412 152 (36.9) 0.159 Gentamicin 26 0 (0.0)* 122 9 (7.4) 0.153 Amox-clav 9 2 (22.2)* 62 18 (29.0) 0.671 K. pneumonia Ampicillin 25 25 (100) 49 49 (100) N/A Ceftriaxone 26 10 (38.5) 47 9 (19.1) 0.071 Ciprofloxacin 19 10 (52.6) 43 13 (30.2) 0.092 Imipenem 10 0 (0.0) 9 0 (0.0) N/A Meropenem 10 0 (0.0) 9 0 (0.0) N/A Nitrofurantoin 20 13 (65.0) 44 27 (61.4) 0.780 TZP 5 1 (20.0) 4 0 (0.0) 0.342 TMP/SMX 19 14 (73.7) 44 9 (20.4) <0.001 Gentamicin 21 1 (4.8) 22 2 (9.1) 0.577 Amox-clav 6 1 (16.7) 6 1 (16.7) 1 P. mirabilis Ampicillin 5 2 (40.0) 13 6 (46.1) 0.882 Ceftriaxone 6 1 (16.7) 15 2 (13.3) 0.865 Ciprofloxacin 6 1 (16.7) 15 2 (13.3) 0.865 Imipenem 1 0 (0.0) 1 1 (100) 0.386 Meropenem 2 0 (0.0) 2 0 (0.0) N/A Nitrofurantoin 6 6 (100) 15 15 (100) 1 TMP/SMX 6 2 (33.3) 15 4 (26.7) 0.821 Gentamicin 4 0 (0.0) 3 1 (33.3) 0.286 Amox-clav 1 1 (100) 3 1 (33.3) 0.540 Values are presented as numbers and percentages (%). *Non-susceptibility includes resistant and intermediate susceptibility isolates.
E. coli: Escherichia coli, K. pneumoniae: Klebsiella pneumoniae, P. mirabilis: Proteus mirabilis, TZP: piperacillin-tazobactam,
TMP/SMX: trimethoprim-sulfamethoxazole, Amox-clav: amoxicillin and clavulanate, N/A: not available
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.